Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.

ABSTRACT:

Rationale & objective

Hyperuricemia has been implicated in the development and progression of chronic kidney disease. Verinurad is a novel, potent, specific urate reabsorption inhibitor. We evaluated the effects on albuminuria of intensive urate-lowering therapy with verinurad combined with the xanthine oxidase inhibitor febuxostat in patients with hyperuricemia and type 2 diabetes mellitus (T2DM).

Study design

Phase 2, multicenter, prospective, randomized, double-blind, parallel-group, placebo-controlled trial.

Setting & participants

Patients 18 years or older with hyperuricemia, albuminuria, and T2DM.

Intervention

Patients randomly assigned 1:1 to verinurad (9mg) plus febuxostat (80mg) or matched placebo once daily for 24 weeks.

Outcomes

The primary en

SUBMITTER: Stack AG 

PROVIDER: S-EPMC8045740 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature